Filing Details

Accession Number:
0000891293-15-000062
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-12-04 18:30:30
Reporting Period:
2015-12-04
Filing Date:
2015-12-04
Accepted Time:
2015-12-04 18:30:30
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
891293 Cti Biopharma Corp CTIC Pharmaceutical Preparations (2834) 911533912
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1557551 Matthew Plunkett 3101 Western Avenue, Suite 600
Seattle WA 98121
Evp, Corporate Development No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2015-12-04 1,500 $0.99 628,584 No 4 S Direct
Common Stock Disposition 2015-12-04 600 $0.99 627,984 No 4 S Direct
Common Stock Disposition 2015-12-04 200 $0.99 627,784 No 4 S Direct
Common Stock Disposition 2015-12-04 200 $0.99 627,584 No 4 S Direct
Common Stock Disposition 2015-12-04 1,100 $0.99 626,484 No 4 S Direct
Common Stock Disposition 2015-12-04 200 $0.99 626,284 No 4 S Direct
Common Stock Disposition 2015-12-04 600 $1.00 625,684 No 4 S Direct
Common Stock Disposition 2015-12-04 100 $1.00 625,584 No 4 S Direct
Common Stock Disposition 2015-12-04 100 $1.00 625,484 No 4 S Direct
Common Stock Disposition 2015-12-04 300 $1.00 625,184 No 4 S Direct
Common Stock Disposition 2015-12-04 200 $1.00 624,984 No 4 S Direct
Common Stock Disposition 2015-12-04 100 $1.00 624,884 No 4 S Direct
Common Stock Disposition 2015-12-04 4,500 $1.00 620,384 No 4 S Direct
Common Stock Disposition 2015-12-04 100 $1.01 620,284 No 4 S Direct
Common Stock Disposition 2015-12-04 200 $1.01 620,084 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. The sale was effected pursuant to a 10b5-1 trading plan.